Loomis, Sayles & Company
VRDN icon

Loomis, Sayles & Company’s Viridian Therapeutics VRDN Stock Holding History

Loomis, Sayles & Company’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-927,717
Closed -$18.1M – 775
2026
Q1 		$18.1M Sell
927,717
-553,418
-37% -$16.4M 0.02% 250
2025
Q4 		$46.1M Sell
1,481,135
-69,193
-4% -$1.9M 0.06% 112
2025
Q3 		$33.5M Buy
1,550,328
+211,856
+16% +$3.82M 0.04% 160
2025
Q2 		$18.7M Sell
1,338,472
-31,884
-2% -$433K 0.02% 250
2025
Q1 		$18.5M Sell
1,370,356
-30,025
-2% -$511K 0.03% 252
2024
Q4 		$26.8M Buy
+1,400,381
New +$30.4M 0.03% 214

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Loomis, Sayles & Company's VRDN Position: Q2 2026 in Review

Loomis, Sayles & Company sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 927,717 shares — an estimated $18.1M sold.

Loomis, Sayles & Company first reported a position in VRDN in Q4 2024 and held it in 6 quarters. The position peaked at $46.1M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Loomis, Sayles & Company reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Loomis, Sayles & Company sold 927,717 Viridian Therapeutics shares in Q2 2026, an estimated $18.1M.
  • Loomis, Sayles & Company first reported a position in Viridian Therapeutics in Q4 2024 and held it in 6 quarters.
  • Loomis, Sayles & Company's Viridian Therapeutics position peaked at $46.1M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.